Victoria Bünger, Stephanie Scholz, Martin Russ, Steffen Weber-Carstens, Jan A Graw
{"title":"Hemolysis, hemolytic markers, and mortality in sepsis: a scoping review.","authors":"Victoria Bünger, Stephanie Scholz, Martin Russ, Steffen Weber-Carstens, Jan A Graw","doi":"10.1186/s40635-025-00786-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite advanced and early treatment in the intensive care unit (ICU), mortality in patients with sepsis remains high. Sepsis is often associated with hemolysis. In the clinical routine, hemolysis is often overlooked, as markers of hemolysis are often not routinely measured. Aim of this scoping literature review is to quantify the incidence and extent of hemolysis in patients with sepsis and the association with mortality.</p><p><strong>Methods: </strong>Systematic literature search in bibliographic databases MEDLINE, EMBASE and Web of Science for sepsis and hemolysis.</p><p><strong>Results: </strong>A total of 3382 studies underwent title-abstract screening and 169 studies were reviewed in full. There were 34 studies with a total of 27,702 patients with sepsis and reported hemolysis or hemolytic markers and clinical outcomes included in the final analyses. Mortality ranged from 5.4 to 78.6% with a mean mortality of 20.1% across all studies. A significant association between hemolysis or hemolytic markers with increased mortality was observed in nine studies.</p><p><strong>Conclusions: </strong>Although significant associations between hemolysis and outcome in patients with sepsis were observed, hemolytic markers are not yet routinely and regularly monitored in clinical routine on the ICU. Hemolytic markers can provide information about disease severity and outcome on ICU admission and during the course of the disease. Future work should focus on identification of reliable markers of hemolysis with a potential for easy and timely measurements ideally at the patients' bedside. With an additional definition of monitoring standards, the potential of hemolysis monitoring for prognostication and therapeutic approaches will emerge.</p>","PeriodicalId":13750,"journal":{"name":"Intensive Care Medicine Experimental","volume":"13 1","pages":"79"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12325840/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intensive Care Medicine Experimental","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40635-025-00786-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite advanced and early treatment in the intensive care unit (ICU), mortality in patients with sepsis remains high. Sepsis is often associated with hemolysis. In the clinical routine, hemolysis is often overlooked, as markers of hemolysis are often not routinely measured. Aim of this scoping literature review is to quantify the incidence and extent of hemolysis in patients with sepsis and the association with mortality.
Methods: Systematic literature search in bibliographic databases MEDLINE, EMBASE and Web of Science for sepsis and hemolysis.
Results: A total of 3382 studies underwent title-abstract screening and 169 studies were reviewed in full. There were 34 studies with a total of 27,702 patients with sepsis and reported hemolysis or hemolytic markers and clinical outcomes included in the final analyses. Mortality ranged from 5.4 to 78.6% with a mean mortality of 20.1% across all studies. A significant association between hemolysis or hemolytic markers with increased mortality was observed in nine studies.
Conclusions: Although significant associations between hemolysis and outcome in patients with sepsis were observed, hemolytic markers are not yet routinely and regularly monitored in clinical routine on the ICU. Hemolytic markers can provide information about disease severity and outcome on ICU admission and during the course of the disease. Future work should focus on identification of reliable markers of hemolysis with a potential for easy and timely measurements ideally at the patients' bedside. With an additional definition of monitoring standards, the potential of hemolysis monitoring for prognostication and therapeutic approaches will emerge.
背景:尽管在重症监护病房(ICU)进行了晚期和早期治疗,脓毒症患者的死亡率仍然很高。败血症常伴有溶血。在临床常规中,溶血经常被忽视,因为溶血指标通常不被常规测量。本文献综述的目的是量化脓毒症患者溶血的发生率和程度及其与死亡率的关系。方法:在MEDLINE、EMBASE和Web of Science等文献数据库中系统检索败血症和溶血相关文献。结果:共有3382项研究进行了标题摘要筛选,169项研究被完整回顾。共有34项研究,共27,702例败血症患者,并报告溶血或溶血标志物和临床结果纳入最终分析。死亡率从5.4到78.6%不等,所有研究的平均死亡率为20.1%。在9项研究中观察到溶血或溶血标志物与死亡率增加之间的显著关联。结论:虽然观察到溶血与脓毒症患者预后之间存在显著相关性,但在ICU的临床常规中尚未常规和定期监测溶血标志物。溶血标志物可以在ICU入院时和病程中提供疾病严重程度和预后的信息。未来的工作应侧重于确定可靠的溶血标志物,以便在患者床边进行简单和及时的测量。随着监测标准的附加定义,溶血监测对预后和治疗方法的潜力将出现。